



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/ *Cancer Care Nova Scotia***

**Guidelines for the Role of Trastuzumab (Herceptin®) in Adjuvant Therapy for
HER2 Positive Breast Cancer**

Approved Use:

Trastuzumab: As **sequential** combination therapy (following adjuvant **chemotherapy**) in patients who have documented evidence of HER2 overexpression (IHC3+ or FISH+), node positive or high risk node negative breast cancer with an ECOG performance status 0-2, for whom adjuvant chemotherapy would be recommended due to high risk of disease recurrence, and who choose to receive systemic chemotherapy.

- This policy recommendation represents a **new guideline document** and an **expansion** (modification) of the current restriction of trastuzumab to include patients with HER2 positive breast cancer receiving adjuvant chemotherapy.